Citas

Total de citas : 232

Citas tipo A 191

Citas tipo B 41

(Actualizado en junio de 2021)

 

  1. Mutations in rpoB and katG genes in Mycobacterium isolates from the Southeast of Mexico

Zenteno-Cuevas, R.; Zenteno, J. C.; Cuellar, A, Cuevas B, Sampieri CL, Riviera JE, Parissi A.

MEMORIAS DO INSTITUTO OSWALDO CRUZ.  Volumen: 104 Número: 3 Páginas: 468-472

ISSN 0074-0276.

Fecha de publicación: MAY 2009

Citas Tipo A: 19

  1. Molecular characterization of drug-resistant and -susceptible Mycobacterium tuberculosis isolated from patients with tuberculosis in Korea. Yoon, Jee-Hyun; Nam, Ji-Sun; Kim, Kyung-Jin; et ál. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE. 2012 Jan;72(1):52-61. doi: 10.1016/j.diagmicrobio.2011.09.010. Epub 2011 Nov 10.
  2. Detection of genomic mutations in katG, inhA and rpoB genes of Mycobacterium tuberculosis isolates using polymerase chain reaction and multiplex allele-specific polymerase chain reaction. Khosravi, Azar Dokht; Goodarzi, Hamed; Alavi, Seyed Mohammad. BRAZILIAN JOURNAL OF INFECTIOUS DISEASES. 2012 Jan-Feb;16(1):57-62.
  3. Multiplex allele specific PCR for rapid detection of extensively drug resistant tuberculosis. Vadwai, Viral; Shetty, Anjali; Rodrigues, Camilla. TUBERCULOSIS. 2012 May;92(3):236-42. doi: 10.1016/j.tube.2012.01.004. Epub 2012 Feb 18.
  4. DNA mutations associated to rifampicin or isoniazid resistance in M. tuberculosis clinical isolates from Sonora, Mexico. Bolado-Martinez, Enrique; Perez-Mendoza, Ansix; Monserrat Alegria-Morquecho, Francisco; et ál. SALUD PUBLICA DE MEXICO. 2012 Mar-Apr;54(2):167-70.
  5. Commentary on the article «Mutations associated with resistance to rifampin and isoniazid in M-tuberculosis clinical isolation in Sonora, Mexico». Samantha, Flores-Trevino; Elvira, Garza-Gonzalez. SALUD PUBLICA DE MEXICO. 2013 Feb; 55(2):150-151.
  6. Predictive Value of Molecular Drug Resistance Testing of Mycobacterium tuberculosis Isolates in Valle del Cauca, Colombia. Ferro, Beatriz E.; Garcia, Pamela K.; Maria Nieto, Luisa; et ál.JOURNAL OF CLINICAL MICROBIOLOGY. 2013 Jul;51(7):2220-4. doi: 10.1128/JCM.00429-13. Epub 2013 May
  7. Increased in vitro fitness of multi and extensively drug-resistant F15/LAM4/KZN strains of Mycobacterium tuberculosis. Naidoo, C. C.; Pillay, M.CLINICAL MICROBIOLOGY AND INFECTION. 2014 Jun;20(6):O361-9. doi: 10.1111/1469-0691.12415. Epub 2013 Nov
  8. Drug resistance and molecular epidemiology of Mycobacterium tuberculosis in Mexico: A systematic review. Flores-Trevino, Samantha; Mendoza-Olazaran, Soraya; Garza-Gonzalez, Elvira. SALUD PUBLICA DE MEXICO. 2014 Jan-Feb;56(1):63-77.
  9. A Systematic Follow-Up of Mycobacterium tuberculosis Drug-Resistance and Associated Genotypic Lineages in the French Departments of the Americas over a Seventeen-Year Period. Millet, Julie; Streit, Elisabeth; Berchel, Mylene; et ál.BIOMED RESEARCH INTERNATIONAL. 2014;2014:689852. doi: 10.1155/2014/689852. Epub 2014 Mar
  10. Characterization of phenotypic and genotypic drug resistance patterns of Mycobacterium tuberculosis isolates from a city in Mexico. Por: Flores-Trevino, Samantha; Morfin-Otero, Rayo; Rodriguez-Noriega, Eduardo; et ál.ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2015 Mar;33(3):181-5. doi: 10.1016/j.eimc.2014.04.005. Epub 2014 Jun
  11. Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities. Vilchèze C, Jacobs WR Jr. MICROBIOL SPECTR. 2014 Aug;2(4):MGM2-0014-2013. doi: 10.1128/microbiolspec.MGM2-0014-2013.
  12. Prevalence and risk factors of drug-resistant tuberculosis in border provinces of Iran. Sahebi L, Ansarin K, Farajnia S, Monfaredan A, Sabour S. POSTGRAD MED. 2015 Aug;127(6):600-6. doi: 10.1080/00325481.2015.1069168. Epub 2015 Jul
  13. Genotypic Detection of rpoB and katG Gene Mutations Associated with Rifampicin and Isoniazid Resistance in Mycobacterium Tuberculosis Isolates: A Local Scenario (Kelantan). Ismail NA, Ismail MF, Noor SS, Camalxaman SN. MALAYS J MED SCI. 2016 Jan;23(1):22-6.
  14. Antibiotic Resistome: Improving Detection and Quantification Accuracy for Comparative Metagenomics. Elbehery AH, Aziz RK, Siam R. OMICS. 2016 Apr;20(4):229-38. doi: 10.1089/omi.2015.0191. Epub 2016 Mar
  15. QSAR based therapeutic management of M. tuberculosis. Ahamad S, Rahman S, Khan FI, Dwivedi N, Ali S, Kim J, Imtaiyaz Hassan M. ARCH PHARM RES. 2017 Jun;40(6):676-694. doi: 10.1007/s12272-017-0914-1. Epub 2017 Apr 29.
  16. Computational discovery of potent drugs to improve the treatment of pyrazinamide resistant Mycobacterium tuberculosis mutants. Jagadeb M, Rath SN, Sonawane A. J CELL BIOCHEM. 2018 Sep;119(9):7328-7338. doi: 10.1002/jcb.27033. Epub 2018 May
  17. Direct Whole-Genome Sequencing of Sputum Accurately Identifies Drug-Resistant Mycobacterium tuberculosis Faster than MGIT Culture Sequencing. Doyle RM, Burgess C, Williams R, Gorton R, Booth H, Brown J, Bryant JM, Chan J, Creer D, Holdstock J, Kunst H, Lozewicz S, Platt G, Romero EY, Speight G, Tiberi S, Abubakar I, Lipman M, McHugh TD, Breuer J. J CLIN MICROBIOL. 2018 Jul 26;56(8). pii: e00666-18. doi: 10.1128/JCM.00666-18. Print 2018 Aug.
  18. In silico discovery of potential drug molecules to improve the treatment of isoniazid-resistant Mycobacterium tuberculosis. Jagadeb M, Rath SN, Sonawane A. J BIOMOL STRUCT DYN. 2019 Aug;37(13):3388-3398. doi: 10.1080/07391102.2018.1515116. Epub 2018 Nov
  19. Characterization of mutations in therpoB gene conferring rifampicin resistance in Mycobacterium tuberculosiscomplex isolated from lymph nodes of slaughtered cattle from South Africa. Bhembe, N.L., Green, E. Braz J Microbiol 51, 1919–1927 (2020). https://doi.org/10.1007/s42770-020-00356-4

Citas Tipo B: 7

  1. Tuberculosis drogorresistente: mecanismos moleculares y métodos diagnósticos. B Cuevas-Córdoba, R Zenteno-Cuevas . ENFERMEDADES INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA. 2010;28(9):621-8
  2. Assessing the utility of three TaqMan probes for the diagnosis of tuberculosis and resistance to rifampin and isoniazid in Veracruz, México. Zenteno-Cuevas R, Cuevas-Cordoba B, Enciso A, Enciso L, Cuellar A. CAN J MICROBIOL. 2012 Mar;58(3):318-25. doi: 10.1139/w11-127. Epub 2012 Feb
  3. Characterization of pncA gene mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Mexico. Cuevas-Córdoba B, Xochihua-González SO, Cuellar A, Fuentes-Domínguez J, Zenteno-Cuevas R. INFECT GENET EVOL. 2013 Oct;19:330-4. doi: 10.1016/j.meegid.2012.12.013. Epub 2013 Jan
  4. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates from high prevalence tuberculosis states in Mexico. Juarez-Eusebio DM, Munro-Rojas D, Muñiz-Salazar R, Laniado-Laborín R, Martinez-Guarneros JA, Flores-López CA, Zenteno-Cuevas R. INFECT GENET EVOL. 2017 Nov;55:384-391. doi: 10.1016/j.meegid.2016.09.012. Epub 2016 Sep
  5. rpoB, katG and inhA mutations in multi-drug resistant strains of Mycobacterium tuberculosis clinical isolates from southeast Mexico. Zenteno-Cuevas R, Cuevas-Córdoba B, Parissi-Crivelli A. ENFERM INFECC MICROBIOL CLIN. 2019 May;37(5):307-313. doi: 10.1016/j.eimc.2018.09.002. Epub 2018 Oct
  6. Whole genomic sequencing as a tool for diagnosis of drug and multidrug-resistance tuberculosis in an endemic region in Mexico. Madrazo-Moya CF1, Cancino-Muñoz I, Cuevas-Córdoba B, González-Covarrubias V, Barbosa-Amezcua M, Soberón X, Muñiz-Salazar R, Martínez-Guarneros A, Bäcker C, Zarrabal-Meza J, Sampieri-Ramirez C, Enciso-Moreno A, Lauzardo M, Comas I, Zenteno-Cuevas R. PLOS ONE. 2019 Jun;5;14(6):e0213046. doi: 10.1371/journal.pone.0213046. eCollection 2019.
  7. Sequencing of the entire rpob gene and characterization of mutations in isolates of Mycobacterium tuberculosis circulating in an endemic tuberculosis setting. Luna JF, Montero H, Sampieri CL, Muñiz-Salazar R, Zenteno-Cuevas R. J GLOB ANTIMICROB RESIST. 2019 Dec;19:98-103. doi: 10.1016/j.jgar.2019.03.001. Epub 2019 Mar 11.

 

 

  1. Drug resistant tuberculosis: molecular mechanisms and diagnostic methods

Cuevas-Córdoba, Betzaida; Zenteno-Cuevas, Roberto

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA Volumen: 28 Número: 9 Páginas: 621-628

ISSN: 0213-005X. DOI: 10.1016/j.eimc.2009.12.005.

Fecha de publicación: NOV 2010

Citas Tipo A: 11

  1. Diagnóstico molecular en tuberculosis: presente y futuro. Carlos Toro Rueda Y Aránzazu Amor Aramendía. MEDICINA RESPIRATORIA 2010,3 (3):53-60.
  2. Métodos diagnósticos moleculares en tuberculosis. Diana Cristina Ortiz Marín, Beatriz Helena Aristizábal. MEDICINA U.P.B. 2013, 32(2):144-150
  3. Resistant and extrapulmonary tuberculosis: two challenges for today’s clinician. Rojas-Puentes JC. REVISTA COLOMBIANA DE NEUMOLOGÍA. 2013 Jul;25(3):136-139
  4. Métodos diagnósticos en tuberculosis; lo convencional y los avances tecnológicos en el siglo xxi. Arévalo Barea AR, Alarcón Terán H, Arévalo Salazar DE. REVISTA MÉDICA LA PAZ. 2015;21(1), 75-85. Disponible en: <http://www.scielo.org.bo/scielo.php?script=sci_arttext&pid=S1726-89582015000100011&lng=es&nrm=iso>. ISSN 1726-8958.
  5. Mutaciones Asociadas A Resistencia A Rifampicina E Isoniacida En Aislamientos Clínicos Del Complejo Mycobacterium tuberculosis De Pacientes Del Hospital Roosevelt. MR Gordillo, HM Ruiz, RL Cortés, J Samayoa, CR Mejia. REVISTA ASOCIACIÓN DE MEDICINA INTERNA DE GUATEMALA. 2015 Mayo – Julio; 19(02):17-54.
  6. Multi-Fluorescence Real-Time PCR Assay for Detection of RIF and INH Resistance of M. tuberculosis. Peng J, Yu X, Cui Z, Xue W, Luo Z, Wen Z, Liu M, Jiang D, Zheng H, Wu H, Zhang S, Li Y. FRONT MICROBIOL. 2016 Apr29;7:618. doi: 10.3389/fmicb.2016.00618. eCollection 2016.
  7. Mycobacterium bovis lymphadenitis, an entity to consider. Pediatría Atención Primaria. Peñafiel-Freire, DM, Resano Abarzuza, MA, Urriza Yeregui, L, Urriza Ripa, I, Niyubahwe, I, Herranz Aguirre, M. REV PEDIATR ATEN PRIMARIA. 2017 April;19(74):147-150.
  8. Determinación de la mutación S315 del gen katG en aislados resistentes a isoniacida de Mycobacterium tuberculosis mediante PCRr-RFLP. Sánchez-Domínguez J, Nicola-Salas E, Morey-León G. REV INFECTIO. 2018;22(4). Doi: 10.22354/in.v22i4.735
  9. Resistencia a los antimicrobianos. Bisso-Andrade A. REV SOC PERU MED INTER. 2018;31(2):50-59.
  10. Antibiotic resistance of Mycobacterium tuberculosis complex in Africa: A systematic review of current reports of molecular epidemiology, mechanisms and diagnostics. Osei Sekyere J, Reta MA, Maningi NE, Fourie PB. J INFECT. 2019 Dec;79(6):550-571. doi: 10.1016/j.jinf.2019.10.006. Epub 2019 Oct 16.
  11. Análisis in silico de algunas mutaciones presentes en el gen pncA de Mycobacterium tuberculosis. Barrientos-Adrian, K. Y., Flores Gracia, J., Amelia-Molina, C., Venegas-Barrera, C., Guevara-Guerrero, G., & Rendón, A.. (2020). Acta universitaria30, e2816. Epub 22 de octubre de 2020.https://doi.org/10.15174/au.2020.2816

Citas Tipo B: 3

  1. Co-infection and risk factors of tuberculosis in a Mexican HIV+ population. Zenteno-Cuevas R, Montes-Villaseñor E, Morales-Romero J, Coronel-Martín del Campo G, Cuevas B. REV SOC BRAS MED TROP. 2011 May-Jun;44(3):282-5.
  2. Assessing the utility of three TaqMan probes for the diagnosis of tuberculosis and resistance to rifampin and isoniazid in Veracruz, México. Zenteno-Cuevas R, Cuevas-Cordoba B, Enciso A, Enciso L, Cuellar A. CAN J MICROBIOL. 2012 Mar;58(3):318-25. doi: 10.1139/w11-127. Epub 2012 Feb
  3. Sequencing of the entire rpob gene and characterization of mutations in isolates of Mycobacterium tuberculosis circulating in an endemic tuberculosis setting. Luna JF, Montero H, Sampieri CL, Muñiz-Salazar R, Zenteno-Cuevas R. J GLOB ANTIMICROB RESIST. 2019 Dec;19:98-103. doi: 10.1016/j.jgar.2019.03.001. Epub 2019 Mar 11.

 

 

 

  1. Co-infection and risk factors of tuberculosis in a Mexican HIV+ population

Zenteno-Cuevas, Roberto; Montes-Villasenor, Evangelina; Morales-Romero, Jaime; Coronel-Martín del Campo, Gastón, Cuevas Betzaida.

REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL Volumen: 44 Número: 3 Páginas: 282-285

ISSN 0037-8682. DOI: 10.1590/S0037-86822011005000034

Fecha de publicación: MAY-JUN 2011

Citas Tipo A: 10

  1. Risk Factors for Developing Active Tuberculosis After the Treatment of Latent Tuberculosis in Adults Infected with Human Immunodeficiency Virus. Amoakwa, Kojo; Martinson, Neil A.; Moulton, Lawrence H.; et ál. OPEN FORUM INFECTIOUS DISEASES. 2015 Jan;2(1): DOI : 10.3844/ajidsp.2013.142.147
  2. A new predictive model for an improved respiratory isolation strategy in HIV-infected patients with PTB. Por: Carugati, M.; Schiroli, C.; Zanini, F.; et ál. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE. 2014 Jul;18(7):831-836.
  3. Clinical and epidemiological profile and prevalence of tuberculosis/HIV co-infection in a regional health district in the state of Maranhao, Brazil. Santos Neto M; da Silva Leita F; de Sousa Rodrigues K; et ál. JORNAL BRASILEIRO DE PNEUMOLOGIA. 2012 Nov-Dec; 38(6): 724-732.
  4. Quality of life aspects of patients with HIV/tuberculosis co-infection. Lemos, Larissa de Araujo; Feijao, Alexsandra Rodrigues; Gir, Elucir; et ál. ACTA PAULISTA DE ENFERMAGEM. 2012; 25(1): 41-47.
  5. Clinical and Sociodemographic Risk Factors for Tuberculosis in Human Immunodeficiency Virus Infected Patients. Paz-Ayar Nibardo, Jose Antonio Mata-Marin, Jesus Gaytan-Martinez, Gloria Huerta-Garcia and Benjamin Acosta-Cazares. AMERICAN JOURNAL OF INFECTIOUS DISEASES. 2013;9(4):142-147. DOI : 10.3844/ajidsp.2013.142.147
  6. When is Tb-Aids Co-Infection Treatment Discontinued? an Analysis of the Situation in Brazil. Silva Camèlo EL, Ribeiro Monteiro de Figueiredo TM, Camèlo Aguila D, Davina da Silva R, Gutiérrez Sánchez R. INTERNATIONAL ARCHIVES OF MEDICINE. 2015:8(239):1-8.
  7. HIV seroprevalence in prisoners in Amapá. Pantoja Vale E, da Silva Carvalho L, da Silva Pereira FC. REV DE EPIDEMIOL CONTROL INFEC SANTA CRUZ DO SUL. 2016;6(3):1-4.
  8. Integrating tuberculosis screening in Kenyan Prevention of Mother-To-Child Transmission programs. Cranmer LM, Langat A, Ronen K, McGrath CJ, LaCourse S, Pintye J, Odeny B, Singa B, Katana A, Nganga L, Kinuthia J, John-Stewart G. INT J TUBERC LUNG DIS. 2017 Mar 1;21(3):256-262. doi: 10.5588/ijtld.16.0478.
  9. Access to diagnosis of tuberculosis in Brazilian medium-sized municipality. de Freitas Quintero MC, Figueiredo Vendramini SH, Sperli Geraldes Santos ML, Rocha Dos Santos M, Gazetta CE, and col. REV SALUD PUBLICA (BOGOTA). 2018 Jan-Feb;20(1):103-109. doi: 10.15446/rsap.V20n1.64177.
  10. Social determinants of pulmonary tuberculosis in Brazil: an ecological study. Zille AI Werneck GL, Luiz RR, Conde MB. BMC PULM MED. 2019 May 8;19(1):87. doi: 10.1186/s12890-019-0855-1.

Citas Tipo B: 1

  1. Whole genomic sequencing as a tool for diagnosis of drug and multidrug-resistance tuberculosis in an endemic region in Mexico. Madrazo-Moya CF1, Cancino-Muñoz I, Cuevas-Córdoba B, González-Covarrubias V, Barbosa-Amezcua M, Soberón X, Muñiz-Salazar R, Martínez-Guarneros A, Bäcker C, Zarrabal-Meza J, Sampieri-Ramirez C, Enciso-Moreno A, Lauzardo M, Comas I, Zenteno-Cuevas R. PLOS ONE. 2019

 

 

  1. Assessing the utility of three TaqMan probes for the diagnosis of tuberculosis and resistance to rifampin and isoniazid in Veracruz, Mexico

Zenteno-Cuevas, Roberto; Cuevas-Córdoba, Betzaida; Enciso, Antonio; et ál.

CANADIAN JOURNAL OF MICROBIOLOGY Volumen: 58 Número: 3 Páginas: 318-325.

ISSN: 0008-4166. DOI: 10.1139/w11-127.

Fecha de publicación: MAR 2012.

Citas Tipo A: 4

  1. Genetic diversity among multidrug-resistant Mycobacterium tuberculosis strains in Mexico. Por: Martinez-Guarneros, Armando; Rastogi, Nalin; Couvin, David; et ál. INFECTION GENETICS AND EVOLUTION. 2013 Mar;14:434-43. doi: 10.1016/j.meegid.2012.12.024. Epub 2013 Jan
  2. Molecular Assessment, Drug-Resistant Profile, and Spacer Oligonucleotide Typing (Spoligotyping) of Mycobacterium tuberculosis Strains From Tamaulipas, Mexico. Bocanegra-Garcia, Virgilio; Garza-Gonzalez, Elvira; Lizeth Cruz-Pulido, Wendy; et ál.JOURNAL OF CLINICAL LABORATORY ANALYSIS. 2014 Mar;28(2):97-103. doi: 10.1002/jcla.21650. Epub 2014 Jan 6.
  3. Multi-Fluorescence Real-Time PCR Assay for Detection of RIF and INH Resistance of M. tuberculosis. Peng J, Yu X, Cui Z, Xue W, Luo Z, Wen Z, Liu M, Jiang D, Zheng H, Wu H, Zhang S, Li Y. FRONT MICROBIOL. 2016 Apr29;7:618. doi: 10.3389/fmicb.2016.00618. eCollection 2016.
  4. Genetic diversity of Mycobacterium tuberculosis and transmission associated with first-line drug resistance: a first analysis in Jalisco, Mexico. Lopez-Avalos G, Gonzalez-Palomar G, Lopez-Rodriguez M, Vazquez-Chacon CA, Mora-Aguilera G, Gonzalez-Barrios JA, Villanueva-Arias JC, Sandoval-Diaz M6 Miranda-Hernández U, Alvarez-Maya I. J GLOB ANTIMICROB RESIST. 2017 Dec;11:90-97. doi: 10.1016/j.jgar.2017.07.004. Epub 2017 Jul 29.

Citas Tipo B: 11

  1. rrs and rpsL mutations in streptomycin-resistant isolates of Mycobacterium tuberculosis from Mexico. Cuevas-Córdoba B, Cuellar-Sánchez A, Pasissi-Crivelli A, Santana-Álvarez CA, Hernández-Illezcas J, Zenteno-Cuevas R. J Microbiol Immunol Infect. 2013 Feb;46(1):30-4. doi: 10.1016/j.jmii.2012.08.020. Epub 2012 Oct
  2. Characterization of pncA gene mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Mexico. Cuevas-Córdoba B, Xochihua-González SO, Cuellar A, Fuentes-Domínguez J, Zenteno-Cuevas R. INFECT GENET EVOL. 2013 Oct;19:330-4. doi: 10.1016/j.meegid.2012.12.013. Epub 2013 Jan
  3. Characterisation of pks15/1 in clinical isolates of Mycobacterium tuberculosis from Mexico. Zenteno-Cuevas, Roberto; Silva-Hernandez, Francisco X.; Mendoza-Damian, Fabiola; et ál. MEMORIAS DO INSTITUTO OSWALDO CRUZ. 2013 Sep;108(6):718-23. doi: 10.1590/0074-0276108062013007.
  4. Description of the population structure and genetic diversity of tuberculosis in Estado de México, a low prevalence setting from Mexico. Zenteno-Cuevas R, Mendoza-Damián F, Muñoz IC, Enciso-Moreno L, Pérez-Navarro LM, Ramírez-Hernández MD, Vázquez-Medina K, Widrobo-García L, Lauzardo M, Enciso-Moreno JA. 2015 Feb;123(2):116-22. doi: 10.1111/apm.12312. Epub 2014 Sep 25.
  5. Mutation at embB codon 306, a potential marker for the identification of multidrug resistance associated with ethambutol in Mycobacterium tuberculosis. Cuevas-Córdoba B, Juárez-Eusebio DM, Almaraz-Velasco R, Muñiz-Salazar R, Laniado-Laborin R, Zenteno-Cuevas R. Antimicrob Agents Chemother. 2015 Sep;59(9):5455-62. doi: 10.1128/AAC.00117-15. Epub 2015 Jun
  6. A first insight into the genetic diversity of Mycobacterium Tuberculosis in Veracruz, Mexico. Almaraz-Velasco R, Munro-Rojas D, Fuentes-Domínguez J, Muñiz-Salazar R, Ibarra-Estela MA, Guevara-Méndez AD, Chaparro-Martinez RI, Perez-Navarro M, Zenteno-Cuevas R. INT J MYCOBACTERIOL. 2017 Jan-Mar;6(1):14-20. doi: 10.4103/2212-5531.201886.
  7. Genetic diversity of drug and multidrug-resistant Mycobacterium tuberculosis circulating in Veracruz, Mexico. Munro-Rojas D, Fernandez-Morales E, Zarrabal-Meza J, Martínez-Cazares MT, Parissi-Crivelli A, Fuentes-Domínguez J, Séraphin MN, Lauzardo M, González-Y-Merchand JA, Rivera-Gutierrez S, Zenteno-Cuevas R. PLoS One. 2018 Mar 15;13(3):e0193626. doi: 10.1371/journal.pone.0193626. eCollection 2018.
  8. rpoB, katG and inhA mutations in multi-drug resistant strains of Mycobacterium tuberculosis clinical isolates from southeast Mexico. Zenteno-Cuevas R, Cuevas-Córdoba B, Parissi-Crivelli A. ENFERM INFECC MICROBIOL CLIN. 2019 May;37(5):307-313. doi: 10.1016/j.eimc.2018.09.002. Epub 2018 Oct
  9. Whole genomic sequencing as a tool for diagnosis of drug and multidrug-resistance tuberculosis in an endemic region in Mexico. Madrazo-Moya CF1, Cancino-Muñoz I, Cuevas-Córdoba B, González-Covarrubias V, Barbosa-Amezcua M, Soberón X, Muñiz-Salazar R, Martínez-Guarneros A, Bäcker C, Zarrabal-Meza J, Sampieri-Ramirez C, Enciso-Moreno A, Lauzardo M, Comas I, Zenteno-Cuevas R. PLOS ONE. 2019
  10. Characterization of Polymorphisms Associated with Multidrug-Resistant Tuberculosis by Whole Genomic Sequencing: A Preliminary Report from Mexico. Zenteno-Cuevas R, Fernandez E, Viveros D, Madrazo-Moya CF, Cancino-Muñoz I, Comas I, Gonzalez-Covarrubias V, Barbosa-Amezcua M, Cuevas-Cordoba B. MICROB DRUG RESIST. 2019 Dec doi: 10.1089/mdr.2019.0054.
  11. Sequencing of the entire rpob gene and characterization of mutations in isolates of Mycobacterium tuberculosis circulating in an endemic tuberculosis setting. Luna JF, Montero H, Sampieri CL, Muñiz-Salazar R, Zenteno-Cuevas R. J GLOB ANTIMICROB RESIST. 2019 Dec;19:98-103. doi: 10.1016/j.jgar.2019.03.001. Epub 2019 Mar 11.

 

 

  1. rrs and rpsL mutations in streptomycin-resistant isolates of Mycobacterium tuberculosis from Mexico

Cuevas-Cordoba, Betzaida; Cuellar-Sanchez, Aremy; Pasissi-Crivelli, Aurora; et ál.

JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION   Volumen: 46 Número: 1 Páginas: 30-34

ISSN: 1684-1182.  DOI: 10.1016/j.jmii.2012.08.020.

Fecha de publicación: FEBRERO 2013.

Citas Tipo A: 22

  1. Drug resistance and molecular epidemiology of Mycobacterium tuberculosis in Mexico: A systematic review. Flores-Trevino, Samantha; Mendoza-Olazaran, Soraya; Garza-Gonzalez, Elvira. SALUD PUBLICA DE MEXICO. 2014 Jan-Feb;56(1):63-77.
  2. Pyrosequencing for rapid detection of tuberculosis resistance in clinical isolates and sputum samples from re-treatment pulmonary tuberculosis patients. Zheng R, Zhu C, Guo Q, Qin L, Wang J, Lu J, Cui H, Cui Z, Ge B, Liu J, Hu Z. BMC INFECT DIS. 2014 Apr 13;14:200. doi: 10.1186/1471-2334-14-200.
  3. Screening for Streptomycin Resistance-Conferring Mutations in Mycobacterium tuberculosis Clinical Isolates from Poland. Jagielski, Tomasz; Ignatowska, Helena; Bakula, Zofia; et ál. PLOS ONE. 2014 Jun 17;9(6):e100078. doi: 10.1371/journal.pone.0100078. eCollection 2014.
  4. Characterization of phenotypic and genotypic drug resistance patterns of Mycobacterium tuberculosis isolates from a city in Mexico. Flores-Trevino, Samantha; Morfin-Otero, Rayo; Rodriguez-Noriega, Eduardo; et ál. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2015 Mar;33(3):181-5. doi: 10.1016/j.eimc.2014.04.005. Epub 2014 Jun 18
  5. Performance of REBA MTB-XDR to detect Extensively Drug-resistant Tuberculosis in an intermediate-burden country. Por: Young Seok Lee, Mi Ran Kang, Hoon Jung, Sang Bong Choi, Kyung-Wook Jo, Tae Sun Shim. JOURNAL OF INFECTION AND CHEMOTHERAPY. 2015 May;21(5):346-51. doi: 10.1016/j.jiac.2014.12.009. Epub 2015 Jan 9.
  6. Identification of mutations conferring streptomycin resistance in multidrug-resistant tuberculosis of China. Por: Li-Li Zhao, Hai-Can Liu, Qing Sun, Tong-Yang Xiao, Xiu-Qin Zhao, Gui-Lian Li, Chun-Yan Zeng, Kang-Lin Wan. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE. 2015 Oct;83(2):150-3. doi: 10.1016/j.diagmicrobio.2015.06.020. Epub 2015 Jul 2.
  7. Characterization of mutations in streptomycin-resistant Mycobacterium tuberculosis isolates in Sichuan, China and the association between Beijing-lineage and dual-mutation in gidB. Honghu Sun, Congcong Zhang, Ling Xiang, Rui Pi, Zhen Guo, Chao Zheng, Song Li, Yuding Zhao, Ke Tang, Mei Luo, Nalin Rastogi, Yuqing Li, Qun Sun. TUBERCULOSIS. 2016 Jan;96:102-6. doi: 10.1016/j.tube.2015.09.004. Epub 2015 Dec 2
  8. Methodological and Clinical Aspects of the Molecular Epidemiology of Mycobacterium tuberculosis and Other Mycobacteria. Jagielski T, Minias A, van Ingen J, Rastogi N, Brzostek A, Żaczek A, Dziadek J. CLIN MICROBIOL REV. 2016 Apr;29(2):239-90. doi: 10.1128/CMR.00055-15
  9. Drug resistance mechanisms and novel drug targets for tuberculosis therapy. Islam MM, Hameed HMA, Mugweru J, Chhotaray C, Wang C, Tan Y, Liu J, Li X, Tan S, Ojima I, Yew WW, Nuermberger E, Lamichhane G, Zhang T. J GENET GENOMICS. 2017 Jan 20;44(1):21-37. doi: 10.1016/j.jgg.2016.10.002. Epub 2016 Oct 11.
  10. Genetic Patterns of rpsL and rrs Genes in Clinical Isolates of Mycobacterium tuberculosis, Isfahan‚ Iran. Nasr Esfahani B ‚ Mirhendi H ‚ Riyahi Zaniani F ‚ Salehi M and Karimi S. MYCOBACT DIS 2017, 7:1
  11. Screening for streptomycin resistance conferring mutations in Mycobacterium tuberculosis isolates from Iran. Rezaei F, Haeili M, Imani Fooladi A, Azari Garmjan GA, Feizabadi MM. J CHEMOTHER. 2017 Feb;29(1):14-18. doi: 10.1080/1120009X.2016.1169619. Epub 2016 Jul 5.
  12. Rapid Detection of Streptomycin-Resistant Mycobacterium tuberculosis by rpsL-Restriction Fragment Length Polymorphism. Karimi S, Mirhendi H, Zaniani FR, Manesh SE, Salehi M, Esfahani BN. ADV BIOMED RES. 2017 Oct 16;6:126. doi: 10.4103/abr.abr_240_16. eCollection 2017.
  13. Molecular Mechanisms of Intrinsic Streptomycin Resistance in Mycobacterium abscessus. Dal Molin M, Gut M, Rominski A, Haldimann K, Becker K, Sander P. ANTIMICROB AGENTS CHEMOTHER. 2017 Dec 21;62(1). pii: e01427-17. doi: 10.1128/AAC.01427-17. Print 2018 Jan.
  14. High Resolution Melting Curve Analysis for Rapid Detection of Streptomycin and Ethambutol Resistance in Mycobacterium tuberculosis. Rezaei F, Haeili M, Fooladi AI, Feizabadi MM. MAEDICA (BUCHAR). 2017 Dec;12(4):246-257.
  15. Frequency of rrs and rpsL mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from Iranian patients. Azar Dokht Khosravi, Nayereh Etemad, Mohammad Hashemzadeh, Solmaz Khandan Dezfuli, Hamed Goodarzi. JOURRANL OF GLOBAL ANTIMICROBIAL RESISTANCE. 2017;9:51-56.
  16. Reduction of the fitness cost of antibiotic resistance caused by chromosomal mutations under poor nutrient conditions. Wenfang Lin,Jie Zeng, Kun Wan, Lu Lv, Lizheng Guo, Xi Li, Xin Yu. ENVIROMENTAL INTERNATIONAL. 2018;120:63-71.
  17. Detection of a streptomycin-resistant Mycobacterium bovis strain through antitubercular drug susceptibility testing of Tunisian Mycobacterium tuberculosis complex isolates from cattle. Djemal SE, Camperio C, Armas F, Siala M, Smaoui S, Messadi-Akrout F, Gdoura R, Marianelli C. BMC VET RES. 2018 Sep 29;14(1):296. doi: 10.1186/s12917-018-1623-9.
  18. The roles of rpsL, rrs, and gidB mutations in predicting streptomycin-resistant drugs used on clinical Mycobacterium tuberculosis isolates from Hebei Province, China. Wang Y, Li Q, Gao H, Zhang Z, Liu Y, Lu J, Dai E. Int J Clin Exp Pathol. 2019 Jul 1;12(7):2713-2721. eCollection 2019.
  19. Genetics and roadblocks of drug resistant tuberculosis. João Perdigão, Isabel Portugal. INFECTION, GENETICS AND EVOLUTION. 2019 Aug;72:113-130.
  20. Phenotypic and Genotypic Characterization of Streptomycin-Resistant Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates in Southern China. Islam MM, Tan Y, Hameed HMA, Chhotaray C, Liu Z, Liu Y, Lu Z, Wang S, Cai X, Gao Y, Cai X, Guo L, Li X, Tan S, Yew WW, Zhong N, Liu J, Zhang T. MICROB DRUG RESIST. 2020 Jan doi: 10.1089/mdr.2019.0245. [Epub ahead of print]
  21. Molecular analysis of streptomycin-resistance associating genes in Mycobacterium tuberculosis isolates from Nepal. Dipti Shrestha, Bhagwan Maharjan, Nan Aye Thida Oo, Norikazu Isoda, Chie Nakajima, Yasuhiko Suzuki. Tuberculosis 2020. Volume 125. doi.org/10.1016/j.tube.2020.101985.
  22. Rapid and economical drug resistance profiling with Nanopore MinION for clinical specimens with low bacillary burden of Mycobacterium tuberculosis. Chan, W.S., Au, C.H., Chung, Y. et al.BMC Res Notes 13, 444 (2020). https://doi.org/10.1186/s13104-020-05287-9

Citas Tipo B: 3

  1. Description of the population structure and genetic diversity of tuberculosis in Estado de Mexico, a low prevalence setting from Mexico. Por: Zenteno-Cuevas, Roberto; Mendoza-Damian, Fabiola; Cansino Munoz, Irving; et ál. APMIS. 2015 Feb;123(2):116-22. doi: 10.1111/apm.12312. Epub 2014 Sep 25.
  2. Characterisation of pks15/1 in clinical isolates of Mycobacterium tuberculosis from Mexico. Zenteno-Cuevas, Roberto; Silva-Hernandez, Francisco X.; Mendoza-Damian, Fabiola; et ál. MEMORIAS DO INSTITUTO OSWALDO CRUZ. 2013 Sep;108(6):718-23. doi: 10.1590/0074-0276108062013007.
  3. Whole genomic sequencing as a tool for diagnosis of drug and multidrug-resistance tuberculosis in an endemic region in Mexico. Madrazo-Moya CF1, Cancino-Muñoz I, Cuevas-Córdoba B, González-Covarrubias V, Barbosa-Amezcua M, Soberón X, Muñiz-Salazar R, Martínez-Guarneros A, Bäcker C, Zarrabal-Meza J, Sampieri-Ramirez C, Enciso-Moreno A, Lauzardo M, Comas I, Zenteno-Cuevas R. PLOS ONE. 2019

 

  

  1. Characterization of pncA gene mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Mexico

Cuevas-Córdoba, Betzaida; Oyuki Xochihua-Gonzalez, Sheila; Cuellar, Aremy; et ál.

INFECTION GENETICS AND EVOLUTION Volumen: 19 Páginas: 330-334.

ISSN: 1567-1348. DOI: 10.1016/j.meegid.2012.12.013.

Fecha de publicación: OCTUBRE 2013.

Citas Tipo A: 18

  1. Drug resistance and molecular epidemiology of Mycobacterium tuberculosis in Mexico: A systematic review. Flores-Trevino, Samantha; Mendoza-Olazaran, Soraya; Garza-Gonzalez, Elvira. SALUD PUBLICA DE MEXICO. 2014 Jan-Feb;56(1):63-77.
  2. Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance. Por: Amel Kevin Alame-Emane, Peng Xu, C. Pierre-Audigier, Véronique C. THE INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE. 2015 Jun;19(6);679-84. doi:10.5588/ijtld.14.0768.
  3. Systematic Review of Mutations in Pyrazinamidase Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis Clinical Isolates. Ramirez-Busby, Sarah M.; Valafar, Faramarz. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2015 Sep;59(9):5267-77. doi: 10.1128/AAC.00204-15. Epub 2015 Jun 15.
  4. A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis. Whitfield, Michael G.; Soeters, Heidi M.; Warren, Robin M.; et ál.PLOS ONE. 2015 Jul 28;10(7):e0133869. doi: 10.1371/journal.pone.0133869. eCollection 2015.
  5. Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT. Whitfield, Michael G.; Warren, Robin M.; Streicher, Elizabeth M.; et ál. JOURNAL OF CLINICAL MICROBIOLOGY. 2015 Nov;53(11):3633-5. doi: 10.1128/JCM.01001-15. Epub 2015 Aug
  6. Pyrazinamide resistance in Mycobacterium tuberculosis develops after resistance to rifampicin and is increasingly common as strains become resistant to additional antibiotics. Alame-Emane AK, P. XuC. Pierre-Audigier, et al. TROPICAL MEDICINE & INTERNATIONAL HEALTH. 2015 August; 20:24-25
  7. Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update. Njire M, Tan Y, Mugweru J, Wang C, Guo J, Yew W, Tan S, Zhang T. ADV MED SCI. 2016 Mar;61(1):63-71. doi: 10.1016/j.advms.2015.09.007. Epub 2015 Oct
  8. Pyrazinamide resistance determined by liquid culture at low pH better correlates withgenetic mutations in MDR tuberculosis isolates.  Pang, Yu; Wang, Zhongdong; Zheng, Huiwen; et ál. JOURNAL OF MICROBIOLOGICAL METHODS.2015 Dec;119:142-4. doi: 10.1016/j.mimet.2015.10.014. Epub 2015 Oct
  9. Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China. Xu P, Wu J, Yang C, Luo T, Shen X, Zhang Y, Nsofor CA, Zhu G, Gicquel B, Gao Q. TUBERCULOSIS. 2016 May;98:56-61. doi: 10.1016/j.tube.2016.02.008. Epub 2016 Mar
  10. Whole genome sequencing to complement tuberculosis drug resistance surveys in Uganda. Ssengooba W1, Meehan CJ, Lukoye D, Kasule GW, Musisi K, Joloba ML, Cobelens FG, de Jong BC. Infect Genet Evol. 2016 Jun;40:8-16. doi: 10.1016/j.meegid.2016.02.019. Epub 2016 Feb 23.
  11. Molecular mechanisms of action, resistance, detection to the first-line anti tuberculosis drugs: Rifampicin and pyrazinamide in the post whole genome sequencing era. Nusrath Unissa A, Hanna LE. Tuberculosis. 2017 Jul;105:96-107. doi: 10.1016/j.tube.2017.04.008. Epub 2017 Apr
  12. A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis. Ramirez-Busby SM, Rodwell TC, Fink L, Catanzaro D, Jackson RL, Pettigrove M, Catanzaro A, Valafar F. SCI REP. 2017 Jun 19;7(1):3790. doi: 10.1038/s41598-017-03452-y.
  13. Estimation of pyrazinamidase activity using a cell-free In vitro synthesis of pnca and its association with pyrazinamide susceptibility in Mycobacterium tuberculosis. Rueda D, Bernard C, Gandy L, Capton E, Boudjelloul R, Brossier F, Veziris N, Zimic M, Sougakoff W. INT J MYCOBACTERIOL. 2018 Jan-Mar;7(1):16-25. doi: 10.4103/ijmy.ijmy_187_17.
  14. Computational insights into pH-dependence of structure and dynamics of pyrazinamidase: A comparison of wild type and mutants. Esmaeeli R, Mehrnejad F, Mir-Derikvand M, Gopalpoor N. J CELL BIOCHEM. 2018 Oct doi: 10.1002/jcb.27543.
  15. Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China. Cao Z, Lan Y, Chen L, Xiang M, Peng Z, Zhang J, Zhang H. Infect Drug Resist. 2019 Sep 30;12:3093-3102. doi: 10.2147/IDR.S222943. eCollection 2019.
  16. High prevalence of phenotypic pyrazinamide resistance and its association with pncAgene mutations in Mycobacterium tuberculosis isolates from Uganda. Resty Naluyange, Gerald Mboowa, Kevin Komakech, Derrick Semugenze, David Patrick Kateete, Willy Ssengooba. PlosOne. May 15, 2020. https://doi.org/10.1371/journal.pone.0232543.
  17. Colorimetric methods for rapid determination of pyrazinamide resistance. Ahmet Ugur Akbal,Belma Durupinar, Ahmet Yilmaz Coban. Internaional Journal of Mycobacteriologu. 2020:9(3). DOI:4103/ijmy.ijmy_42_20.
  18. Computational modeling and bioinformatic analyses of functional mutations in drug target genes in Mycobacterium tuberculosis  Singh P., Jamal S., Ahmed F., (…), Ehtesham N.Z., Hasnain S.E. 2021   Computational and Structural Biotechnology Journal, 19, pp. 2423-2446.

Citas Tipo B: 2

  1. Whole genomic sequencing as a tool for diagnosis of drug and multidrug-resistance tuberculosis in an endemic region in Mexico. Madrazo-Moya CF1, Cancino-Muñoz I, Cuevas-Córdoba B, González-Covarrubias V, Barbosa-Amezcua M, Soberón X, Muñiz-Salazar R, Martínez-Guarneros A, Bäcker C, Zarrabal-Meza J, Sampieri-Ramirez C, Enciso-Moreno A, Lauzardo M, Comas I, Zenteno-Cuevas R. PLOS ONE. 2019
  2. Characterization of Polymorphisms Associated with Multidrug-Resistant Tuberculosis by Whole Genomic Sequencing: A Preliminary Report from Mexico. Zenteno-Cuevas R, Fernandez E, Viveros D, Madrazo-Moya CF, Cancino-Muñoz I, Comas I, Gonzalez-Covarrubias V, Barbosa-Amezcua M, Cuevas-Cordoba B. MICROB DRUG RESIST. 2019 Dec doi: 10.1089/mdr.2019.0054. 

 

 

  1. Saliva: A Fluid of Study for OMICS

Cuevas-Cordoba, Betzaida; Santiago-Garcia, Juan.

OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY Volumen: 18 Número: 2 Páginas: 87-97.

ISSN: 1536-2310. DOI: 10.1089/omi.2013.0064.

Fecha de publicación: FEBRERO 1 2014.

Citas Tipo A: 63

  1. Pregnancy-Induced Gingivitis and OMICS in Dentistry: In Silico Modeling and in Vivo Prospective Validation of Estradiol-Modulated Inflammatory Biomarkers. Por:Gursoy, Mervi; Zeidan-Chulia, Fares; Kononen, Eija; et ál. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY.  2014 Sep;18(9):582-90. doi: 10.1089/omi.2014.0020. Epub 2014 Jul
  2. Proteomics and Proteogenomics Approaches for Oral Diseases.Bragazzi, Nicola Luigi; Pechkova, Eugenia; Nicolini, Claudio. ADVANCES IN PROTEIN CHEMISTRY AND STRUCTURAL BIOLOGY. 2014 Jul;95:125-62. doi: 10.1016/B978-0-12-800453-1.00004-X.
  3. Recent developments in sample-pretreatment techniques for mass spectrometry-based metabolomics.Raterink, Robert-Jan; Lindenburg, Peter W.; Vreeken, Rob J.; et ál. TRAC-TRENDS IN ANALYTICAL CHEMISTRY. 2014 Oct; 61: 157-167
  4. Nutri-metabolomics Applied to Taste Perception Phenotype: Human Subjects with High and Low Sensitivity to Taste of Fat Differ in Salivary Response to Oleic Acid.Mounayar, Rana; Morzel, Martine; Brignot, Helene; et ál. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY. 2014 Nov;18(11):666-72. doi: 10.1089/omi.2014.0108. Epub 2014 Oct
  5. Speeksel als diagnostische vloeistof. Eci VeermanEci VeermanA. Chapter in book: Speeksel en speekselklieren. November 2014. DOI: 10.1007/978-90-368-0387-8_24
  6. Characterization of resting versus stimulated saliva fingerprints using Middle-Infrared Spectroscopy assisted by Principal Component Analysis.Badea, Iulia; Crisan, Maria; Fetea, Florinela; et ál.ROMANIAN BIOTECHNOLOGICAL LETTERS. 2014 NOV-DEC; 19 (6):9817-9826
  7. UPLC-QTOF-ESI (+) MS and direct MS injection used to fingerprint resting and stimulated saliva profiles: preliminary results.Badea, Iulia Clara; Crisan, Maria; Pop, Raluca; et ál. STUDIA UNIVERSITATIS BABES-BOLYAI CHEMIA. 2014 DEC;59(4): 7-16
  8. Investigation of quinocetone-induced mitochondrial damage and apoptosis in HepG2 cells and compared with its metabolites. Keyu Zhang, Xiaoyang Wang, Chunmei Wang, Haihong Zheng,Tao Li, Sui Xiao, Mi Wang, Chenzhong Fei, Lifang Zhang, Feiqun Xue. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY. 2015 Feb; 39(2):555-567. DOI: 10.1016/j.etap.2015.01.017
  9. Effects of pre-analytical processes on blood samples used in metabolomics studies.Yin, Peiyuan; Lehmann, Rainer; Xu, Guowang. ANALYTICAL AND BIOANALYTICAL CHEMISTRY.  2015 Jul;407(17):4879-92. doi: 10.1007/s00216-015-8565-x. Epub 2015 Mar
  10. Longitudinal evaluation of salivary profile from children with dental caries before and after treatment.Fidalgo, Tatiana K. S.; Freitas-Fernandes, Liana B.; Almeida, Fabio C. L.; et ál. 2015 Jun;11(3):583-593
  11. Interleukin 1β—A Potential Salivary Biomarker for Cancer Progression? Por:Adi Idris, Nur B Ghazali, David Koh. BIOMARKERS IN CANCER. 2015 Jun;7: 25-29. DOI: 10.4137/BIC.S25375
  12. Proteomics, Biomarkers and HIV-1: A Current Perspective. Por: Maire Rose Donnelly, Pawel Ciborowski. PROTEOMICS CLINICAL APPLICATIONS. 2016 Feb;10(2):110-25. doi: 10.1002/prca.201500002. Epub 2015 Jul 8.
  13. The foodomics approach for discovering biomarkers of food consumption in nutrition studies.Bordoni, Alessandra; Capozzi, Francesco. CURRENT OPINION IN FOOD SCIENCE.2015 Aug;4:124-128.
  14. Saliva proteome profiling reveals potential salivary biomarkers for detection of oral cavity squamous cell carcinoma.Wu, Chih-Ching; Chu, Hao-Wei; Hsu, Chia-Wei; et ál. 2015 Oct;15(19):3394-404. doi: 10.1002/pmic.201500157. Epub 2015 Aug 20.
  15. Point-of-care diagnosis of periodontitis using saliva: technically feasible but still a challenge. Ji, Suk; Choi, Youngnim. FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY. 2015 Sep 3;5:65. doi: 10.3389/fcimb.2015.00065. eCollection 2015.
  16. Human salivary proteome a resource of potential biomarkers for oral cancer. Sivadasan, Priya; Gupta, Manoj Kumar; Sathe, Gajanan J.; et ál.JOURNAL OF PROTEOMICS. 2015 Sep;127( SI ): 89-95
  17. Current and Evolving Technologies. J. Robert Chang, Enkhtsetseg Purev, Winston Kuo. Chapter in book: Genomics, Personalized Medicine and Oral Disease September 2015. DOI: 10.1007/978-3-319-17942-1_2
  18. Salivary metabolomics in the diagnosis of oral cancer and periodontal diseases.J J W Mikkonen, S P Singh, M Herrala, R Lappalainen, S Myllymaa, A M Kullaa. JOURNAL OF PERIODONTAL RESEARCH. 2016 Aug;51(4):431-7. doi: 10.1111/jre.12327. Epub 2015 Oct
  19. Biobanks in Oral Health: Promises and Implications of Post-Neoliberal Science and Innovation. Birch K, Dove ES, Chiappetta M, Gürsoy UK. OMICS. 2016 Jan;20(1):36-41. doi: 10.1089/omi.2015.0123. Epub 2015 Nov 19.
  20. Zebrafish as a Model for Systems Medicine R&D: Rethinking the Metabolic Effects of Carrier Solvents and Culture Buffers Determined by (1)H NMR Metabolomics. Akhtar MT, Mushtaq MY, Verpoorte R, Richardson MK, Choi YH. OMICS. 2016 Jan;20(1):42-52. doi: 10.1089/omi.2015.0119. Epub 2015 Dec 15.
  21. The Neonatal Salivary Transcriptome. Maron JL. COLD SPRING HARB PERSPECT MED. 2015 Dec 18;6(3):a026369. doi: 10.1101/cshperspect.a026369.
  22. Salivary Antimicrobial Peptides in Early Detection of Periodontitis. Güliz N. Güncü, Dogukan Yilmaz, Eija Könönen, Ulvi K. Gürsoy. FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY. 2015 Dec 24;5:99. doi: 10.3389/fcimb.2015.00099. eCollection 2015.
  23. A Systems Biology Approach to Reveal Putative Host-Derived Biomarkers of Periodontitis by Network Topology Characterization of MMP-REDOX/NO and Apoptosis Integrated Pathways. Zeidán-Chuliá F, Gürsoy M, Neves de Oliveira BH, Özdemir V, Könönen E, Gürsoy UK. Front Cell Infect Microbiol. 2016 Jan 11;5:102. doi: 10.3389/fcimb.2015.00102. eCollection 2015.
  24. Noninvasive metabolic profiling for painless diagnosis of human diseases and disorders. Mal M. FUTURE SCI OA. 2016 Jun 10;2(2):FSO106. doi: 10.4155/fsoa-2015-0014. eCollection 2016 Jun.
  25. Analysis of matrix metalloproteinases, especially MMP-8, in gingival creviclular fluid, mouthrinse and saliva for monitoring periodontal diseases. Sorsa, Timo; Gursoy, Ulvi K.; Nwhator, Solomon; et ál. PERIODONTOLOGY 2000.2016 Feb;70(1): 142-163.
  26. Influence of saliva on the oral microbiota. Marsh, Philip D.; Thuy Do; Beighton, David; et ál. PERIODONTOLOGY 2000. 2016 Feb;70(1):80-92.
  27. Ultra-deep and quantitative saliva proteome reveals dynamics of the oral microbiome. Grassl N, Kulak NA, Pichler G, Geyer PE, Jung J, Schubert S, Sinitcyn P, Cox J, Mann M. GENOME MED. 2016 Apr 21;8(1):44. doi: 10.1186/s13073-016-0293-0.
  28. Characteristics of human saliva proteome and peptidome. S. A. Kolesov, E. N. Fedulova, A. E. Lavrova. HUM PHYSIOL. 2016 Agug 18. 42:463-468.
  29. Prediction of Periodontal Inflammation via Metabolic Profiling of Saliva. Kuboniwa M, Sakanaka A, Hashino E, Bamba T, Fukusaki E,Amano A. J Dent Res. 2016 Nov;95(12):1381-1386. doi: 10.1177/0022034516661142. Epub 2016 Jul 29.
  30. Mannose-binding lectin gene polymorphism in relation to periodontal infection. Liukkonen A, He Q, Gürsoy UK, Pussinen PJ, Gröndahl-Yli-Hannuksela K, Liukkonen J, Sorsa T, Suominen AL, Huumonen S, Könönen E. J Periodontal Res. 2017 Jun;52(3):540-545. doi: 10.1111/jre.12420. Epub 2016 Sep 14.
  31. A serum metabolomics-based profile in low bone mineral density postmenopausal women. Miyamoto T, Hirayama A, Sato Y, Koboyashi T, Katsuyama E, Kanagawa H, Miyamoto H, Mori T, et al. Bone. 2017 Feb;95:1-4. doi: 10.1016/j.bone.2016.10.027. Epub 2016 Oct 29.
  32. Metabolomics of Head and Neck Cancer: A Mini-Review. Shin JM, Kamarajan P, Fenno JC, Rickard AH, Kapila YL. FRONT PHYSIOL. 2016 Nov 8;7:526. eCollection 2016.
  33. Current state of salivaomics and metabolomic profiling as novel diagnostics for biomarker research and applications in oral cancer and personalized medicine. Simi Thankappan, N Sherin. TROPICAL JOURNAL OF MEDICAL RESEARCH. 2017;20(2):127-131.DOI: 10.4103/tjmr.tjmr_28_16. Epub 2016 Dec.
  34. Salivary PH Changes in Liver Cirrhosis and Hepatocellular Carcinoma. Maha Hussein., et al.  EC GASTROENTEROLOGY AND DIGESTIVE SYSTEM. 2016: 99-106.
  35. Comprehensive review of trends and analytical strategies applied for biological samples preparation and storage in modern medical lipidomics: State of the art. Kamil Jurowski, Kamila Kochan, Justyna Walczak, Małgorzata Barańska,Wojciech Piekoszewski, Bogusław Buszewski. TRENDS IN ANALYTICAL CHEMISTRY. 2017 Jan;86:276-289.
  36. Salivary biomarkers and proteomics: future diagnostic and clinical utilities. Castagnola M, Scarano E, Passali GC, Messana I, Cabras T, Iavarone F, Di Cintio G, Fiorita A, et al. ACTA OTORHINOLARYNGOL ITAL. 2017 Apr;37(2):94-101. doi: 10.14639/0392-100X-1598.
  37. Identification of a discriminative metabolomic fingerprint of potential clinical relevance in saliva of patients with periodontitis using 1H nuclear magnetic resonance (NMR) spectroscopy. Rzeznik M, Triba MN, Levy P, Jungo S, Botosoa E, Duchemann B, Le Moyec L, Bernaudin JF, Savarin P, Guez D. PLoS One. 2017 Aug 24;12(8):e0182767. doi: 10.1371/journal.pone.0182767. eCollection 2017.
  38. Saliva and the Control of Its Secretion. 2nd Jörgen Ekström, Nina Hylén, Castagnola Massimo, Irene Messana. Chapter in book: Dysphagia Medical Radiology. Publisher: Springer Berlin HeidelbergEditors: Olle Ekberg. December 2017. DOI: 10.1007/174_2017_481.
  39. Tissue and Blood Biomarkers in Lung Cancer: A Review. Michael J Duffy, Ken O’Byrne. Chapter in Advances in clinical chemistry 86. December 2017. DOI: 10.1016/bs.acc.2018.05.001
  40. Developing and Standardizing a Protocol for Quantitative Proton Nuclear Magnetic Resonance (1H NMR) Spectroscopy of Saliva. Gardner A, Parkes HG, Carpenter GH, So PW. J PROTEOME RES. 2018 Apr 6;17(4):1521-1531. doi: 10.1021/acs.jproteome.7b00847. Epub 2018 Mar 13.
  41. Quantitation of the cellular content of saliva and buccal swab samples. Theda C, Hwang SH, Czajko A, Loke YJ, Leong P, Craig JM. SCI REP. 2018 May 2;8(1):6944. doi: 10.1038/s41598-018-25311-0.
  42. Saliva in the «Omics» era: A promising tool in paediatrics. Pappa E, Kousvelari E, Vastardis H. Oral Dis. 2019 Jan;25(1):16-25. doi: 10.1111/odi.12886. Epub 2018 Jun 11.
  43. Role of Salivary Biomarkers in Oral Cancer. Zohaib Khurshid Sultan, M S Zafar , Rabia sannam Khan, et al. Chapter in book: Advances in Clinical Chemistry Publisher: Elsevier Editors: Gregory Makowski. July 2018.Advances in clinical chemistry 86:1-51. DOI: 10.1016/bs.acc.2018.05.002
  44. Top-down proteomic profiling of human saliva in multiple sclerosis patients. Manconi B, Liori B, Cabras T, Vincenzoni F, Iavarone F, Lorefice L, Cocco E, Castagnola M, Messana I, Olianas A. J PROTEOMICS. 2018 Sep 15;187:212-222. doi: 10.1016/j.jprot.2018.07.019. Epub 2018 Aug 4.
  45. Potential role of nuclear magnetic resonance spectroscopy to identify salivary metabolite alterations in patients with head and neck cancer. Mikkonen JJW, Singh SP, Akhi R, Salo T, Lappalainen R, González-Arriagada WA, Ajudarte Lopes M, Kullaa AM, Myllymaa S. Oncol Lett. 2018 Nov;16(5):6795-6800. doi: 10.3892/ol.2018.9419. Epub 2018 Sep 7.
  46. Osteonecrosis of the Jaw. Sotirios Tetradis, Laurie McCauley, Tara Aghaloo. Chapter in book: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. September 2018. DOI: 10.1002/9781119266594.ch120
  47. Grading system for periodontitis by analyzing levels of periodontal pathogens in saliva. Kim EH, Joo JY, Lee YJ, Koh JK, Choi JH, Shin Y, Cho J, Park E, Kang J, Lee K, Bhak J, Kim BC, Lee JY. PLoS One. 2018 Nov 26;13(11):e0200900. doi: 10.1371/journal.pone.0200900. eCollection 2018.
  48. The role of gingival gelatinases and salivary collagenases in the periodontal conditions. Pillai, Adithya R.; Lakshmi, R. Ponnu; Purushothaman, V.; Vinothkumar, K. DRUG INVENTION TODAY. 2019 Feb; 12(2):298-302.
  49. Association between periodontal pathogens and systemic disease. Bui FQ, Almeida-da-Silva CLC, Huynh B, Trinh A, Liu J, Woodward J, Asadi H, Ojcius DM. Biomed J. 2019 Feb;42(1):27-35. doi: 10.1016/j.bj.2018.12.001. Epub 2019 Mar 2.
  50. Evaluation of Biochemical Parameters Present in the Saliva of Patients with Chronic Periodontitis: Results from a Meta-Analysis. Di Lenardo D, Silva FRPD, de Carvalho França LF, Carvalho JDS, Alves EHP, Vasconcelos DFP. GENET TEST MOL BIOMARKERS. 2019 Apr;23(4):255-263. doi: 10.1089/gtmb.2017.0272.
  51. Biochemical changes in saliva of cows with inflammation: A pilot study. Contreras-Aguilar MD, Monkeviciene I, Ceron JJ, Silinskas I, Vallejo-Mateo PJ, Tecles F, Martinez-Subiela S, Tvarijonaviciute A, Zelvyte R. RES VET SCI. 2019 Jun;124:383-386. doi: 10.1016/j.rvsc.2019.04.019. Epub 2019 May 4.
  52. Role of salivary transcriptomics as potential biomarkers in oral cancer: A systematic review. Patil S, Arakeri G, Alamir AWH, Awan KH, Baeshen H, Ferrari M, Patil S, Fonseca FP, Brennan PA. J ORAL PATHOL MED. 2019 Nov;48(10):871-879. doi: 10.1111/jop.12895. Epub 2019 Jun 25.
  53. Specimen Collection for Translational Studies in Hidradenitis Suppurativa. Byrd AS, Dina Y, Okoh UJ, Quartey QQ, Carmona-Rivera C, Williams DW, Kerns ML, Miller RJ, Petukhova L, Naik HB, Barnes LA, Shipman WD, Caffrey JA, Sacks JM, Milner SM, Aliu O, Broderick KP, Kim D, et al. SCI REP. 2019 Aug 21;9(1):12207. doi: 10.1038/s41598-019-48226-w.
  54. HS-SPME-GC-MS approach for the analysis of volatile salivary metabolites and application in a case study for the indirect assessment of gut microbiota. Campanella B, Onor M, Lomonaco T, Benedetti E, Bramanti E. ANAL BIOANAL CHEM. 2019 Nov;411(28):7551-7562. doi: 10.1007/s00216-019-02158-6. Epub 2019 Oct 22.
  55. Mapping Relative Differences in Human Salivary Gland Secretions by Dried Saliva Spot Sampling and nanoLC-MS/MS. Schulte F, Hasturk H, Hardt M. Proteomics. 2019 Oct;19(20):e1900023. doi: 10.1002/pmic.201900023. Epub 2019 Sep 26.
  56. Saliva as a non-invasive tool for assessment of metabolic and inflammatory biomarkers in children. Tvarijonaviciute A, Martinez-Lozano N, Rios R, Marcilla de Teruel MC, Garaulet, M, Cerón JJ. CLINICAL NUTRITION. 2019 Nov 7. pii: S0261-5614(19)33129-2. doi: 10.1016/j.clnu.2019.10.034.
  57. Oral squamous cell carcinoma diagnosed from saliva metabolic profiling. iaowei Song, Xihu Yang, Rahul Narayanan, Vishnu Shankar, Sathiyaraj Ethiraj, Xiang Wang, Ning Duan, Yan-Hong Ni, Qingang Hu, and  Richard N. Zare. PNAS July 14, 2020 117 (28) 16167-16173; first published June 29, 2020; https://doi.org/10.1073/pnas.2001395117
  58. Metabolomics in head and neck cancer: A summary of findings. Ravi Kasiappan, Pachiyappan Kamarajan, Yvonne L.Kapila. Translational Systems Medicine and Oral Disease.2020. https://doi.org/10.1016/B978-0-12-813762-8.00005-0
  59. Salivary biomarkers for the diagnosis and monitoring of oral and systemic diseases. Pereira de Lima, Manoel; Fernandes Dantas, Ruth Venâncio; Mendes, Jefferson Lucas; da Costa Neto, Raimundo Euzébio; et al. Rev. cuba. Estomatol. 2020; 57(1): e2139, ene.-mar. 2020. ID: biblio-1126489.
  60. Saliva for the diagnosis of COVID-19. Rabia Sannam Khan , Hamza Ur Rehman& Ihtesham Ur Rehman. Saliva for the diagnosis of COVID-19. Rabia Sannam Khan , Hamza Ur Rehman  & Ihtesham Ur Rehman. Applied Spectroscopy Reviews. 2020; 55 (9-10).https://doi.org/10.1080/05704928.2020.1809442
  61. Cytopathology of Saliva in COVID-19 Patients: Preliminary Study on Five Patients of COVID-19. Mohammad Zulkarnain1†, Rostika Flora2†*, Nyiayu Fauziah3, Citra Dewi3, Eny Rahmawati4, Yusri Yusri5, Lisa Dewi6, Benny Darori7, Danny Kusuma Aerosta8, Krisna Murti3. Open Access Macedonian Journal of Medical Sciences. 2021 Jan 23; 9(A):68-72.. https://doi.org/10.3889/oamjms.2021.5572.
  62. A metabolomic profile predictive of new osteoporosis or sarcopenia development         . Miyamoto K., Hirayama A., Sato Y., (…), Yoshimura N., Miyamoto T.           2021   Metabolites, 11(5), art. no. 278.
  63. Longitudinal saliva omics responses to immune perturbation: a case study. George Mias, Vikas Vikram Singh, Lavida R. K. Rogers, et all. January 2021Scientific Reports 11(1). DOI: 10.1038/s41598-020-80605-6

Citas Tipo B: 0

 

 

  1. Mutations conferring resistance to first- and second-line drugs in multidrug-resistant Mycobacterium tuberculosisclinical isolates in southeast Mexico

Zenteno-Cuevas, Roberto; Xochihua-Gonzalez, Oyuki; Cuevas-Cordoba, Betzaida; et ál.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS Volumen: 45 Número: 6 Páginas: 671-673.

ISSN: 0924-8579. DOI: 10.1016/j.ijantimicag.2015.02.006.

Fecha de publicación: JUNIO 2015.

Citas Tipo A: 1

  1. Acquired Immunodeficiency Syndrome A Forensic Perspective. de Villiers M. J Leg Med. 2017 Jul-Dec;37(3-4):389-461. doi: 10.1080/01947648.2017.1385040.

Citas Tipo B: 4

  1. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates from high prevalence tuberculosis states in Mexico. Juarez-Eusebio DM, Munro-Rojas D, Muñiz-Salazar R, Laniado-Laborín R, Martinez-Guarneros JA, Flores-López CA, Zenteno-Cuevas R. INFECT GENET EVOL. 2017 Nov;55:384-391. doi: 10.1016/j.meegid.2016.09.012. Epub 2016 Sep
  2. rpoB, katG and inhA mutations in multi-drug resistant strains of Mycobacterium tuberculosis clinical isolates from southeast Mexico. Zenteno-Cuevas R, Cuevas-Córdoba B, Parissi-Crivelli A. ENFERM INFECC MICROBIOL CLIN. 2019 May;37(5):307-313. doi: 10.1016/j.eimc.2018.09.002. Epub 2018 Oct
  3. Whole genomic sequencing as a tool for diagnosis of drug and multidrug-resistance tuberculosis in an endemic region in Mexico. Madrazo-Moya CF1, Cancino-Muñoz I, Cuevas-Córdoba B, González-Covarrubias V, Barbosa-Amezcua M, Soberón X, Muñiz-Salazar R, Martínez-Guarneros A, Bäcker C, Zarrabal-Meza J, Sampieri-Ramirez C, Enciso-Moreno A, Lauzardo M, Comas I, Zenteno-Cuevas R. PLOS ONE. 2019
  4. Sequencing of the entire rpob gene and characterization of mutations in isolates of Mycobacterium tuberculosis circulating in an endemic tuberculosis setting. Luna JF, Montero H, Sampieri CL, Muñiz-Salazar R, Zenteno-Cuevas R. J GLOB ANTIMICROB RESIST. 2019 Dec;19:98-103. doi: 10.1016/j.jgar.2019.03.001. Epub 2019 Mar 11.

 

 

  1. Mutation at embB Codon 306, a Potential Marker for the Identification of Multidrug Resistance Associated with Ethambutol in Mycobacteriumtuberculosis

Cuevas-Cordoba, Betzaida; Maria Juarez-Eusebio, Dulce; Almaraz-Velasco, Raquel; et ál.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. Volumen: 59 Número: 9 Páginas: 5455-5462.

Print ISSN: 0066-4804. Online ISSN: 1098-6596.  DOI: 10.1128/AAC.00117-15.

Fecha de publicación: SEPTIEMBRE 2015.

Citas Tipo A: 21

  1. Association between embB Codon 306 Mutations, Phenotypic Resistance Profiles, and Genotypic Characterization in Clinical Mycobacterium tuberculosis Isolates from Hebei, China. Li Y, Wang Y, Zhang Z, Gao H, Wang H, Cao J, Zhang S, Liu Y, Lu J, Xu Z, Dai E. Antimicrob Agents Chemother. 2016 Nov 21;60(12):7295-7302. Print 2016 Dec.
  2. Whole genome analysis of an MDR Beijing/W strain of Mycobacterium tuberculosis with large genomic deletions associated with resistance to isoniazid. Zhang Q1, Wan B, Zhou A, Ni J, Xu Z, Li S, Tao J, Yao Y. Gene. 2016 May 15;582(2):128-36. doi: 10.1016/j.gene.2016.02.003. Epub 2016 Feb 4.
  3. Drug resistance mechanisms and novel drug targets for tuberculosis therapy. Islam MM, Hameed HMA, Mugweru J, Chhotaray C, Wang C, Tan Y, Liu J, Li X, Tan S, Ojima I, Yew WW, Nuermberger E, Lamichhane G, Zhang T. J Genet Genomics. 2017 Jan 20;44(1):21-37. doi:10.1016/j.jgg.2016.10.002. Epub 2016 Oct
  4. Drug resistance and Mycobacterium tuberculosis strain diversity in TB/HIV co-infected patients in Ho Chi Minh city, Vietnam. Mai TQ, Van Anh NT, Hien NT, Lan NH, Giang DC, Hang PTT, Lan NTN, Marais BJ, Sintchenko V. J Glob Antimicrob Resist. 2017 Sep;10:154-160. doi:10.1016/j.jgar.2017.07.003. Epub 2017 Jul
  5. Draft Genome Sequence of the First Confirmed Isolate of Multidrug-Resistant Mycobacterium tuberculosis in Tasmania. Gautam SS, Mac Aogáin M, O’Toole RF. Genome Announc. 2017 Nov 2;5(44). pii: e01230-17. doi: 10.1128/genomeA.01230-17.
  6. Molecular epidemiology of tuberculosis in Tasmania and genomic characterisation of its first known multi-drug resistant case. Gautam SS, Mac Aogáin M, Cooley LA, Haug G, Fyfe JA, Globan M, O’Toole RF. PLoS One. 2018 Feb 21;13(2):e0192351. doi: 10.1371/journal.pone.0192351. eCollection 2018.
  7. Relapse Versus Reinfection of Recurrent Tuberculosis Patients in a National Tuberculosis Specialized Hospital in Beijing, China. Zong Z, Huo F, Shi J, Jing W, Ma Y, Liang Q, Jiang G, Dai G, Huang H, Pang Y. Front Microbiol. 2018 Aug 14;9:1858. doi: 10.3389/fmicb.2018.01858. eCollection 2018.
  8. Mutations of Mycobacterium tuberculosis induced by anti-tuberculosis treatment result in metabolism changes and elevation of ethambutol resistance. Sun L, Zhang L, Wang T1, Jiao W, Li Q, Yin Q, Li J, Qi H, Xu F, Shen C, Xiao J, Liu S, Mokrousov I, Huang H, Shen A. Infect Genet Evol. 2019 Aug;72:151-158. doi: 10.1016/j.meegid.2018.09.027. Epub 2018 Oct
  9. Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases. Huh HJ, Kim SY, Jhun BW, Shin SJ, Koh WJ. Infect Genet Evol. 2019 Aug;72:169-182. doi: 10.1016/j.meegid.2018.10.003. Epub 2018 Oct
  10. The relationship between embb306 and embb406 mutations and ethambutol resistant in Mycobacterium tuberculosis isolated from patiens in west of Iran. Mohammadi B, Mohajeri P, Rouhi S, Ramazanzadeh R. Med J Islam Repub Iran. 2018 Nov 24;32:117. doi: 10.14196/mjiri.32.117. eCollection 2018.
  11. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis. Al-Mutairi NM, Ahmad S, Mokaddas E, Eldeen HS, Joseph S. BMC Infect Dis. 2019 Jan 3;19(1):3. doi: 10.1186/s12879-018-3638-z.
  12. Understanding lipidomic basis of iron limitation induced chemosensitization of drug-resistant Mycobacterium tuberculosis. Pal R, Hameed S, Kumar P, Singh S, Fatima Z. 3 Biotech. 2019 Apr;9(4):122. doi: 10.1007/s13205-019-1645-4. Epub 2019 Mar 5.
  13. Genetic diversity and drug susceptibility profiles of Mycobacterium tuberculosis obtained from Saint Peter’s TB specialized Hospital, Ethiopia. Damena D, Tolosa S, Hailemariam M, Zewude A, Worku A, Mekonnen B, Mohammed T, Admasu A, Chimusa ER, Mihret A, Abebe T, Ameni G. PLoS One. 2019 Jun 24;14(6):e0218545. doi: 10.1371/journal.pone.0218545. eCollection 2019.
  14. Finding New Ways to Combat Multidrug-Resistant Tuberculosis. Faridgohar M. Microb Drug Resist. 2020 Jan;26(1):71-80. doi: 10.1089/mdr.2018.0353. Epub 2019 Sep
  15. Whole genome enrichment approach for rapid detection of Mycobacterium tuberculosis and drug resistance-associated mutations from direct sputum sequencing. Soundararajan L., Kambli P., Priyadarshini S., Gupta R., Ramprasad V.L. 2020, 121, art. no. 101915.
  16. Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol Zhang, Lu and Zhao, Yao and Gao, Yan and Wu, Lijie and Gao, Ruogu and Zhang, Qi and Wang, et al American Association for the Advancement of Science. 2020;368 (6496). Doi:10.1126/science.aba9102
  17. Mycobacterial ethambutol responsive genes and implications in antibiotics resistance. Xiaohong Xiang, Zhen Gong, Wanyan Deng, Qingyu Sun & Jianping Xie. Journal of Drug Targeting, (2021)29:3, 284-293, DOI: 10.1080/1061186X.2020.1853733
  18. Análisis in silico de algunas mutaciones presentes en el gen pncA de Mycobacterium tuberculosis. Barrientos-Adrian, K. Y., Flores Gracia, J., Amelia-Molina, C., Venegas-Barrera, C., Guevara-Guerrero, G., & Rendón, A.. (2020). Acta universitaria30, e2816. Epub 22 de octubre de 2020.https://doi.org/10.15174/au.2020.2816
  19. Mohammadi B, Ramazanzadeh R, Rouhi S, Mohajeri P, Nouri B. Point-Mutations in embB306 Gene and Their Association with Resistance to Ethambutol in Mycobacterium tuberculosis in Clinical Isolates. J Adv Med Biomed Res. 2019; 27 (125) :43-48 URL: http://zums.ac.ir/journal/article-1-5809-en.html
  20. Mutations inembB Gene of Mycobacterium tuberculosis Resistant to Ethambutol: A Systematic Review and Meta-Analysis. Mohammadi, B., Ramazanzadeh, R., Nouri, B., & Rouhi, S. (2020). Frequency of Codon 306 International journal of preventive medicine11, 112. https://doi.org/10.4103/ijpvm.IJPVM_114_19
  21. Molecular Characteristics and Drug Resistance of Mycobacterium tuberculosis Isolate Circulating in Shaanxi Province, Northwestern China. Jian YangTianhua ZhangXiaoping XianShow all 8 authorsJunyang Wang. March 2021Microbial Drug Resistance. DOI: 10.1089/mdr.2020.0496

Citas Tipo B: 2

  1. Whole genomic sequencing as a tool for diagnosis of drug and multidrug-resistance tuberculosis in an endemic region in Mexico. Madrazo-Moya CF1, Cancino-Muñoz I, Cuevas-Córdoba B, González-Covarrubias V, Barbosa-Amezcua M, Soberón X, Muñiz-Salazar R, Martínez-Guarneros A, Bäcker C, Zarrabal-Meza J, Sampieri-Ramirez C, Enciso-Moreno A, Lauzardo M, Comas I, Zenteno-Cuevas R. PLOS ONE. 2019
  2. Characterization of Polymorphisms Associated with Multidrug-Resistant Tuberculosis by Whole Genomic Sequencing: A Preliminary Report from Mexico. Zenteno-Cuevas R, Fernandez E, Viveros D, Madrazo-Moya CF, Cancino-Muñoz I, Comas I, Gonzalez-Covarrubias V, Barbosa-Amezcua M, Cuevas-Cordoba B. MICROB DRUG RESIST. 2019 Dec doi: 10.1089/mdr.2019.0054.

 

 

  1. Transcriptional profiles discriminate patients with pulmonary tuberculosis from non-tuberculous individuals depending on the presence of non-insulin diabetes mellitus.

Carmen J. Serrano · Betzaida Cuevas-Córdoba · Noé Macías-Segura · Rosa Angélica González-Curiel · Víctor Yordani Martínez-Balderas · Leonor Enciso-Moreno · Peter Small · Rogelio Hernández-Pando · José Antonio Enciso-Moreno.

CLINICAL IMMUNOLOGY. Volumen: 162 Número: 1 Páginas: 107-117.

ISSN: 1521-6616. DOI: 10.1016/j.clim.2015.11.008.

Fecha de publicación: ENERO 2016.

Citas Tipo A: 5

  1. An adverse immune-endocrine profile in patients with tuberculosis and type 2 diabetes. Fernández R, Díaz A, D’Attilio L, Bongiovanni B, Santucci N, Bertola D, Besedovsky H, Del Rey A, Bay ML, Bottasso O. Tuberculosis (Edinb). 2016 Dec;101:95-101. doi: 10.1016/j.tube.2016.09.001. Epub 2016 Sep 12.
  2. miR-30c is specifically repressed in patients with active pulmonary tuberculosis. Spinelli SV, Fernández RDV, Zoff L, Bongiovanni B, Díaz A, D’Attilio L, Santucci N, Alvarez T, Marchesini MM, Bogue C, Bay ML, Bottasso OA. Tuberculosis (Edinb). 2017 Jul;105:73-79. doi: 10.1016/j.tube.2017.04.004. Epub 2017 Apr
  3. Metabolomics applied to the discovery of tuberculosis and diabetes mellitus biomarkers. Salgado-Bustamante M, Rocha-Viggiano AK, Rivas-Santiago C, Magaña-Aquino M, López JA, López-Hernández Y. Biomark Med. 2018 Sep;12(9):1001-1013. doi: 10.2217/bmm-2018-0050. Epub 2018 Jul 25.
  4. Performance of diagnostic and predictive host blood transcriptomic signatures for Tuberculosis disease: A systematic review and meta-analysis. Humphrey Mulenga, Chambrez-Zita Zauchenberger, Erick W. Bunyasi, Stanley Kimbung Mbandi, Simon C. Mendelsohn, Benjamin Kagina, Adam Penn-Nicholson, Thomas J. Scriba, Mark Hatherill. Plos One. August 21, 2020. https://doi.org/10.1371/journal.pone.0237574
  5. Screening of potential biomarkers for distinguishing between latent and active tuberculosis in children using bioinformatics analysis. Shao, M., Wu, F., Zhang, J., Dong, J., Zhang, H., Liu, X., Liang, S., Wu, J., Zhang, L., Zhang, C., & Zhang, W. (2021).Medicine100(5), e23207. https://doi.org/10.1097/MD.0000000000023207

Citas Tipo B: 4

  1. Improvement in the Diagnosis of Tuberculosis Combining Mycobacterium Tuberculosis Immunodominant Peptides and Serum Host Biomarkers. López-Ramos JE, Macías-Segura N, Cuevas-Córdoba B, Araujo-García Z, Bastián Y, Castañeda-Delgado JE, y col. Arch Med Res. 2018 Apr;49(3):147-153.e1. doi: 10.1016/j.arcmed.2018.07.003. Epub 2018 Jul 20.
  2. Diagnostic accuracy of combinations of serological biomarkers for identifying clinical tuberculosis. Araujo Z, Macias-Segura N, Lopez-Ramos JE, De Waard JH, Vanegas M, Patarroyo MA, Salgado A, Enciso-Moreno JA. J Infect Dev Ctries. 2018 Jun 30;12(6):429-441. doi: 10.3855/jidc.9554.
  3. Glycerophospholipid Metabolism Alterations in Patients with Type 2 Diabetes Mellitus and Tuberculosis Comorbidity. López-Hernández Y, Lara-Ramírez EE, Salgado-Bustamante M, López JA, Oropeza-Valdez JJ, Jaime-Sánchez E, Castañeda-Delgado JE, Magaña-Aquino M, Murgu M, Enciso-Moreno JA. Arch Med Res. 2019 Feb;50(2):71-78. doi: 10.1016/j.arcmed.2019.05.006. Epub 2019 Jun
  4. Evaluation of the transcriptional immune biomarkers in peripheral blood from Warao indigenous associate with the infection by Mycobacterium tuberculosis. Araujo Z, Palacios A, Enciso-Moreno L, Lopez-Ramos JE, Wide A, Waard JH, Rivas-Santiago B, Serrano CJ, Bastian-Hernandez Y, Castañeda-Delgado JE, Enciso-Moreno JA. Rev Soc Bras Med Trop. 2019 May 16;52:e20180516. doi: 10.1590/0037-8682-0516-2018.

 

 

  1. Improvement in the Diagnosis of Tuberculosis Combining Mycobacterium Tuberculosis Immunodominant Peptides and Serum Host Biomarkers.

López-Ramos JE, Macías-Segura N, Cuevas-Córdoba B, Araujo-García Z, Bastián Y, Castañeda-Delgado JE, y col

ARCH MED RES. Volumen: 49 Número:3 Páginas147-153.

ISSN: 0188-4409. DOI: 10.1016/j.arcmed.2018.07.003. Epub 2018 Jul 20.

Fecha de publicación: ABRIL 2018

Citas Tipo A: 7

  1. Serum antibody profiles in individuals with latent Mycobacterium tuberculosis infection. Maekura R, Kitada S, Osada-Oka M, Tateishi Y, Ozeki Y, Fujicawa T, Miki M, Jyunnko O, Mori M1, Matsumoto S. Microbiol Immunol. 2019 Mar;63(3-4):130-138. doi: 10.1111/1348-0421.12674. Epub 2019 Apr
  2. Immune Biomarkers for Diagnosis and Treatment Monitoring of Tuberculosis: Current Developments and Future Prospects. Yong YK, Tan HY, Saeidi A, Wong WF, Vignesh R, Velu V, Eri R, Larsson M, Shankar EM. Front Microbiol. 2019 Dec 18;10:2789. doi: 10.3389/fmicb.2019.02789. eCollection 2019.
  3. Biomarcadores da tuberculose: uma revisão da literatura.Souza, W. M. de, & Hermes, D. M. Revista Eletrônica Científica Da UERGS. 2019. 5(1), 28-47. https://doi.org/10.21674/2448-0479.51.28-47
  4. Human tuberculosis and Mycobacterium tuberculosis complex: A review on genetic diversity, pathogenesis and omics approaches in host biomarkers discovery. Kanabalan R.D., Lee L.J., Lee T.Y., (…), Ismail R., Chin V.K. Microbiological Research.2021. 246, art. no. 126674.
  5. Clinical Significance of M1/M2 Macrophages and Related Cytokines in Patients with Spinal Tuberculosis. Hawkes, Michael and Wang, Liang and Shang, Xiaoqian and Qi, Xinwei and Ba, Derong and Lv, Jie and Zhou, Xuan and Wang, Hao and Shaxika, Nazierhan and Wang, Jing and Ma, Xiumi. Disease Markers. 2020. https://doi.org/10.1155/2020/2509454
  6. Diagnostic value of CXCR3 and its ligands in spinal tuberculosis. Shang, X., Wang, L., Liu, Y., Liu, X., Lv, J., Zhou, X. … Ma, X. (2021). Experimental and Therapeutic Medicine, 21, 73. https://doi.org/10.3892/etm.2020.9505.
  7. Study on the relationship between CXCR3 and its ligands and tubal tuberculosis Sun H., Fan J., Shang X., (…), Wang J., Ma X.            2021   Life Sciences, 272, art. no. 119047.

 

Citas Tipo B: 2

  1. Evaluation of the transcriptional immune biomarkers in peripheral blood from Warao indigenous associate with the infection by Mycobacterium tuberculosis. Araujo Z, Palacios A, Enciso-Moreno L, Lopez-Ramos JE, Wide A, Waard JH, Rivas-Santiago B, Serrano CJ, Bastian-Hernandez Y, Castañeda-Delgado JE, Enciso-Moreno JA. Rev Soc Bras Med Trop. 2019 May 16;52:e20180516. doi: 10.1590/0037-8682-0516-2018.
  2. Determinant Factors Of Tuberculosis Among Warao Indigenous From The Venezuelan Delta: Genetic And Immunity. Zaida Araujo, Aimé Tillett, Jacobus H de Waard. January 2020Acta Bioethica 21(2):116-13.

 

 

  1. rpoB, katG and inhA mutations in multi-drug resistant strains of Mycobacterium tuberculosis clinical isolates from southeast Mexico

Zenteno-Cuevas R, Cuevas-Córdoba B, Parissi-Crivelli A.

ENFERM INFECC MICROBIOL CLIN. Volumen: 37, Número:5, Páginas :307-313.

ISSN: 0213-005X. DOI: 10.1016/j.eimc.2018.09.002. Epub 2018 Oct 11.

Fecha de publicación: 2019 May

Citas Tipo A: 3

  1. Genotypic Characterization of katG, inhA, and ahpC in Isoniazid-Resistant Mycobacterium tuberculosis Clinical Isolates in Shanghai, China. Cao X, Zhan Q, Guo Y, Yang J , Liu Y , et al. Jundishapur J Microbiol. Online ahead of Print ; 12(11):e95713. doi: 10.5812/jjm.95713.
  2. Two Novel katG Mutations Conferring Isoniazid Resistance in Mycobacterium tuberculosis. Hsu Li-Yu, Lai Li-Yin, Hsieh Pei-Fang, Lin Tzu-Lung, Lin Wan-Hsuan, Tasi Hsing-Yuan, Lee Wei-Ting, Jou Ruwen, Wang Jin-Town. Frontiers in Microbiology. 2020;11. DOI:10.3389/fmicb.2020.01644.
  3. Analysis for characteristics of genetic mutations among multi-drug resistant Mycobacterium tuberculosis (MDR-TB) isolates from Zhejiang Province. ZHAO Gang, JIA Qing-jun, WU Yi-fei, HUANG Yin-yan, TANG Lei-ming, ZENG Mei-chun. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(1): 66-71. doi: 10.16462/j.cnki.zhjbkz.2021.01.013

Citas Tipo B: 0

 

 

  1. Whole genomic sequencing as a tool for diagnosis of drug and multidrug-resistance tuberculosis in an endemic region in Mexico

Madrazo-Moya CF, Cancino-Muñoz I, Cuevas-Córdoba B, González-Covarrubias V, Barbosa-Amezcua M, Soberón X, Muñiz-Salazar R, Martínez-Guarneros A, Bäcker C, Zarrabal-Meza J, Sampieri-Ramirez C, Enciso-Moreno A, Lauzardo M, Comas I, Zenteno-Cuevas R.

PLoS One. Volumen: 5;Número: 14(6); Páginas: e0213046. doi: 10.1371/journal.pone.0213046.

ISSN: 1932-6203. DOI 10.1371/journal.pone.0213046. eCollection 2019.

Fecha de publicación: 2019 Jun

Citas Tipo A: 5

  1. Pharmacogenomics principles and applications on medical practice. Duque R.R., Soca P.E.M. Revista Habanera de Ciencias Medicas.2020. 19(6), art. no. 6.
  2. Prediction ofMycobacterium tuberculosis pyrazinamidase function based on structural stability, physicochemical and geometrical descriptors. Rydberg Roman Supo-Escalante , Aldhair Médico , Eduardo Gushiken, Gustavo E. Olivos-Ramírez, Yaneth Quispe, Fiorella Torres, et al. Plos One.July 31, 2020. https://doi.org/10.1371/journal.pone.0235643.
  3. MutVis: Automated framework for analysis and visualization of mutational Analysis on drug resistance-associated mutations of multi-drug resistant Mycobacterium tuberculosis based on whole-genome sequencing in China Mm, G., Tingting, Y., Guilian, L., Rong, C., Haican, L., Qian, G., Kanglin, W., Shuidong, F.. Chinese Journal of Endemiology. 2020;41(5):770-775.
  4. signatures in pathogenic bacterial strains. Prasanna A., Niranjan V.  Infection, Genetics and Evolution. 2021, 91, art. no. 104805.
  5. Reporting practices for genomic epidemiology of tuberculosis: a systematic review of the literature using STROME-ID guidelines as a benchmark. Brianna Cheng, Marcel A Behr, Benjamin P Howden, et al. March 2021. The Lancet Microbe 2(3):e115-e129. DOI: 10.1016/S2666-5247(20)30201-9.

Citas Tipo B: 1

  1.  Whole genomic sequencing based genotyping reveals a specific X3 sublineage restricted to Mexico and related with multidrug resistance. Jiménez-Ruano, A.C., Madrazo-Moya, C.F., Cancino-Muñoz, I., Mejía-Ponce, P.M., Licona-Cassani, C., Comas, I., Muñiz-Salazar, R., Zenteno-Cuevas, R. Scientific Reports. 2021;11(1).

 

  1. Characterization of Polymorphisms Associated with Multidrug Resistant Tuberculosis by Whole Genomic Sequencing: A Preliminary Report from Mexico

Zenteno-Cuevas R, Fernandez E, Viveros D, Madrazo-Moya CF1, Cancino-Muñoz I, Comas I, Gonzalez-Covarrubias V, Barbosa-Amezcua M, Cuevas-Cordoba B.

MICROB DRUG RESIST. doi: 10.1089/mdr.2019.0054

ISSN: 1931-8448

Fecha de publicación: Online Ahead of Print: 2019 Dec 23

Citas Tipo A: 1

  1. Burmistrova, I.A., Samoylova, A.G., Vaniev, E.V., Tyulkova, T.E., Vasilyeva, I.A., Balasanyants, G.S. Drug resistance of M. tuberculosis (historical aspects, current level of knowledge). Tuberculosis and Lung Diseases. 2020;98(1):54-61.

Citas Tipo B: 0

 

 

15. Allele frequency of ACE2 variants and its association with blood pressure.

Lozano-Gonzalez K, Padilla-Rodríguez E, Texis T, Gutiérrez MN, Rodríguez-Dorantes M, Cuevas-Córdoba B, Mino-León D, Sánchez-García S, Gonzalez-Covarrubias V.

DNA and Cell Biology. Doi: 10.1089/dna.2020.5804.

ISSN: 1044-5498 Online ISSN: 1557-7430. FI 3.191.

Published Online:5 Oct 2020.

Citas Tipo A: 1

  1. Disparities in COVID-19 severities and casualties across ethnic groups around the globe and patterns of ACE2 and PIR variants. Shoily S.S., Ahsan T., Fatema K., Sajib A.A.2021   Infection, Genetics and Evolution, 92, art. no. 104888.

Citas Tipo B: 1

  1. Genotyping NUDT15*3 rs1166855232 reveals higher frequency of potential adverse effects of thiopurines in Natives and Mestizos from Mexico. Tomas Texis · Cintia Guzmán-Cruz, Mauricio Rodríguez-Dorantes, Sergio Sánchez-García, et all. Jun 2021 · Pharmacological Reports.
Publicado en Páginas